J&J's new ketamine-like depression drug Spravato off to 'very, very strong start,' company says
April 16, 2019 at 11:34 AM EDT
The FDA approved Johnson & Johnson's Spravato, or esketamine, last month for treatment-resistant depression. J&J on Tuesday said the first patients have been treated and up to 800 clinics are certified to administer the drug.
